NCT07209202Recruiting
Fructose Intestinal Gluconeogenesis
Fructose Metabolism Effects on the Liver: Unraveling the Role of Defective Intestinal GNG in Individuals With Obesity
Source: ClinicalTrials.gov · Last updated 6 Mar 2026
Brief summary (registry, in English)
This study will test the hypothesis that within a defined range of fructose intake, the ability to convert fructose to glucose (via gluconeogenesis) in the small intestine plays a protective role for the liver, shielding it from the deleterious effects of fructose. We will investigate whether this protective effect of the intestine is impaired in individuals with obesity.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 30 Sept 2025
- Start date
- 2 Mar 2026
- Primary completion date
- 30 Jun 2030
- Lead sponsor
- Touro University, California
- Diseases
- Obesity
- NCT number
- NCT07209202
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 2 Mar 2026 to the primary completion date, 30 Jun 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of any anti-diabetic medications or hypolipidemic agents in the past six months;
Other illness
- Report of HIV or hepatitis B or C infection;
- History of cancer, other than basal cell or squamous cell carcinoma or kidney disease stage 3 or higher or patients currently on dialysis;
- History of surgical procedure for obesity;
- History of other conditions known to affect insulin sensitivity and lipid metabolism (e.g., polycystic ovary syndrome), history of galactosemia, hereditary fructose intolerance, or who test positive for fructose malabsorption at screening;
Lab values
- Type 1 or 2 diabetes mellitus (including fasting glucose ≥126 mg/dL, HgbA1c ≥6.5%);
- History of liver disease or AST and ALT 2x above the upper limit of normal;
- Fasting triglyceride \> 300 mg/dl; total cholesterol levels above the 95th percentile for age and sex;
- Hemoglobin (Hgb) \<12.5g/d or hematocrit\<3x Hgb value;
Other
- Pregnancy or lactation within the past six months;
- Change in body weight \>5% in the past six months (by self-report);
- Known intolerance to acetaminophen.
Who the study is looking for
- BMI 30 to 38 kg/m2 (obese group) or BMI 19 to 25 kg/m2 (lean group)
Age in the registry: 20 years to 55 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Touro University California Coordinator of this site? Confirm its status | Vallejo | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.